Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Paid Sick Leave Could Ease Burden for Colorectal Cancer Patients

January 1, 2016
By Anna Azvolinsky
Article

Paid sick leave benefits could alleviate some of the financial burden patients with colorectal cancer incur during treatment and boost their job retention.

Paid sick leave benefits could alleviate some of the financial burden patients with colorectal cancer (CRC) incur during treatment and boost their job retention, according to a survey-based study published in JAMA.

Christine M. Veenstra, MD, MSHP, a medical oncologist specializing in colorectal cancer at the University of Michigan, and colleagues analyzed mail and telephone surveys of patients with stage III CRC between 2011 and 2013.

The survey found that 55% of CRC patients retained their jobs following their cancer diagnosis; 59% of survey responders with paid sick leave retained their job through their treatment compared with 33% of those who did not have paid sick leave (P < .001).

Patients who were able to retain their jobs were more likely to be men, married, white, and without other illnesses. They were also more likely to be educated and to have a higher annual income and private health insurance.

Patients who did not have access to paid leave reported significantly higher personal financial burden compared with those who did not receive paid leave, including the need to borrow money (28% vs 18%; P < .001), difficulties making credit card payments (29% vs 14%; P < .001), and reduced spending on food and clothing (50% vs 35%; P < .001).

Patients in the study filled out surveys 4 months prior to cancer treatment and 12 months following treatment. Job retention was defined as employment at both diagnosis and a mean of 8 months following diagnosis.

Of the 567 patients who responded to the survey, 56% had paid sick leave from their employer. Of the responders, 58% were male, 28% had less than a high school education, and 35% reported an annual household income of less than $50,000.

As many as 40% of workers in the Unites States do not have paid sick leave from their employer and sick leave is not mandated under the Affordable Care Act or the Family and Medical Leave Act. Such a benefit is also not part of health insurance coverage in the United States. The study suggests that there are significant negative consequences for workers who do not have access to paid sick leave and are diagnosed with serious health conditions such as CRC.

The limitations of the study are that the data analyzed came only from those who responded to the survey and that data on the specific reasons for job change or loss was not captured.

Recent Videos
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Related Content
Advertisement

Results from MATTERHORN showed durvalumab plus FLOT improved EFS and OS compared with placebo plus FLOT in patients with gastric/GEJ cancers.

FDA Approves Durvalumab Plus FLOT in Resectable Gastric/GEJ Cancers

Tim Cortese
November 25th 2025
Article

Results from MATTERHORN showed durvalumab plus FLOT improved EFS and OS compared with placebo plus FLOT in patients with gastric/GEJ cancers.


Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.


The safety profile of zanidatamab plus chemotherapy with or without tislelizumab was consistent with the known profiles of each individual agent.

Zanidatamab-Based Regimens Exhibit Improved PFS in Gastroesophageal Cancers

Roman Fabbricatore
November 17th 2025
Article

The safety profile of zanidatamab plus chemotherapy with or without tislelizumab was consistent with the known profiles of each individual agent.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Results from the phase 3 COMPETE trial demonstrated that 177Lu-edotreotide improved PFS and ORR compared with everolimus in patients with GEP-NETs.

FDA Accepts New Drug Application for 177Lu-Edotreotide in GEP-NETs

Tim Cortese
November 14th 2025
Article

Results from the phase 3 COMPETE trial demonstrated that 177Lu-edotreotide improved PFS and ORR compared with everolimus in patients with GEP-NETs.


Neoadjuvant Cemiplimab/SBRT Yields Improved DFS in Resectable HCC

Neoadjuvant Cemiplimab/SBRT Yields Improved DFS in Resectable HCC

Ariana Pelosci
November 12th 2025
Article

DFS rates at 2 years were improved with cemiplimab plus SBRT vs cemiplimab alone in patients with resectable hepatocellular carcinoma.

Related Content
Advertisement

Results from MATTERHORN showed durvalumab plus FLOT improved EFS and OS compared with placebo plus FLOT in patients with gastric/GEJ cancers.

FDA Approves Durvalumab Plus FLOT in Resectable Gastric/GEJ Cancers

Tim Cortese
November 25th 2025
Article

Results from MATTERHORN showed durvalumab plus FLOT improved EFS and OS compared with placebo plus FLOT in patients with gastric/GEJ cancers.


Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.


The safety profile of zanidatamab plus chemotherapy with or without tislelizumab was consistent with the known profiles of each individual agent.

Zanidatamab-Based Regimens Exhibit Improved PFS in Gastroesophageal Cancers

Roman Fabbricatore
November 17th 2025
Article

The safety profile of zanidatamab plus chemotherapy with or without tislelizumab was consistent with the known profiles of each individual agent.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Results from the phase 3 COMPETE trial demonstrated that 177Lu-edotreotide improved PFS and ORR compared with everolimus in patients with GEP-NETs.

FDA Accepts New Drug Application for 177Lu-Edotreotide in GEP-NETs

Tim Cortese
November 14th 2025
Article

Results from the phase 3 COMPETE trial demonstrated that 177Lu-edotreotide improved PFS and ORR compared with everolimus in patients with GEP-NETs.


Neoadjuvant Cemiplimab/SBRT Yields Improved DFS in Resectable HCC

Neoadjuvant Cemiplimab/SBRT Yields Improved DFS in Resectable HCC

Ariana Pelosci
November 12th 2025
Article

DFS rates at 2 years were improved with cemiplimab plus SBRT vs cemiplimab alone in patients with resectable hepatocellular carcinoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.